Full Text View
Tabular View
No Study Results Posted
Related Studies
Thrombin Regulated Platelet Activation
This study is currently recruiting participants.
Verified by Vanderbilt University, March 2009
First Received: March 2, 2009   Last Updated: March 31, 2009   History of Changes
Sponsored by: Vanderbilt University
Information provided by: Vanderbilt University
ClinicalTrials.gov Identifier: NCT00855296
  Purpose

Thrombin is the most potent activator of platelets, and platelet activation is a hallmark of thrombosis. Coronary artery disease (CAD) is the major cause of mortality and morbidity in the United States and other industrialized countries, and thrombotic sequelae are the key cause of death in diabetes.

The accumulation of thrombin at sites of vascular injury provides one of the major mechanisms of recruiting platelets into a hemostatic plug. Thrombin works by activation of the G protein-coupled protease activated receptors PAR1 and PAR4 on human platelets to initiate signaling cascades leading to increases in [Ca]i, secretion of autocrine activators, trafficking of adhesion molecules to the plasma membrane, and shape change, which all promote platelet aggregation. The thrombin receptors work in a progressive manner, with PAR1 activated at low thrombin concentrations, and PAR4 recruited at higher thrombin concentrations. As direct thrombin inhibitors become widely used in clinical practice, it is important to assess their effects on vascular function. Our hypothesis is that PAR1 and PAR4 do not signal through the same G protein pathways, and that PAR4 is not a strong platelet agonist. To investigate this hypothesis, the investigators will study the G protein pathways downstream of PAR4, and assess ex-vivo platelet responsiveness to thrombin, PAR1, and PAR4 agonist peptides, both in normal human subjects, and along the stages of pathology, from patients with stable angina as well as unstable angina who are undergoing angioplasty. Similarly, the investigators will examine platelet function in patients with metabolic syndrome as well as diabetes, along the continuum from insulin resistance to full-blown disease. These studies will provide deeper insight into the G protein pathways used by PARs. They will elucidate the contribution of PAR receptors to normal platelet function as well as the abnormal platelet activation in thrombotic states. The long term goal is to understand the implications for PAR receptors as therapeutic targets for anti-platelet therapies that may carry less bleeding risk.


Condition
Coronary Artery Disease
Acute Coronary Syndrome

MedlinePlus related topics: Coronary Artery Disease
U.S. FDA Resources
Study Type: Observational
Study Design: Case Control, Prospective
Official Title: Thrombin Regulated Platelet Activation

Further study details as provided by Vanderbilt University:

Biospecimen Retention:   Samples With DNA

Biospecimen Description:

Whole blood


Estimated Enrollment: 200
Study Start Date: September 2006
Estimated Study Completion Date: September 2011
Estimated Primary Completion Date: June 2011 (Final data collection date for primary outcome measure)
  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

Patients undergoing angioplasty

Criteria

Inclusion Criteria:

  • Age: over 18, Sex: male and female.
  • Patients who undergo clinically indicated coronary angiography and/or PCI. Patients in Group 1 (elective PCI) include those presented with stable angina (ACC definition for stable angina).
  • Coronary angiography reveals severe stenosis (>70%) that requires PCI.
  • Patients in Group 2 (elective PCI in subjects with diabetes) include those who present with stable angina, or with findings on non-invasive testing (exercise or pharmacologic stimulation with imaging by nuclear perfusion imaging or stress echocardiography) in whom coronary angiography reveals severe stenosis (>70%) that requires PCI.
  • Patients in Group 2 (ACS) include those presented with unstable angina or non-ST elevation myocardial infarction (as defined by the ACC).
  • Coronary angiography reveals severe stenosis (>70%) that requires PCI.

Exclusion Criteria:

  • Significant left main coronary artery disease.
  • Severely impaired left ventricular systolic function (EF<35%).
  • Prior treatment with enoxaparin, Bivalirudin (or other thrombin inhibitors), Warfarin, or thrombolytic agents <48 hours.
  • Prior history of myocardial infarction (<6 weeks). Prior history of stroke (<6 weeks).
  • Prior history of coronary intervention (<6 weeks).
  • History of HIV/AIDS.
  • The patients will be identified in the following manner:
  • All subjects will be picked from a pool of patients diagnosed with stable angina and diabetes from the Vanderbilt Page-Campbell Heart Institute at Vanderbilt University Medical Center and undergo a complete history and physical examination.
  • Patients with acute coronary syndrome will be referred from the acute cardiology patient service at Vanderbilt University Medical Center.
  • Subjects with hematologic, renal (creatinine > 2.0 mg/dl), hepatic, inflammatory, and neoplastic disorders, and those who sustained a recent (< 1 month) myocardial infarction, ACS, or stroke will be excluded. Patients who used nonsteroidal anti-inflammatory drugs, corticosteroids, or hormone replacement therapy will also be excluded.
  • Pregnancy will be excluded in women of child bearing potential by measurement of urine ß-HCG (it is standard of care to determine if a woman is pregnant prior to elective PCI and will be screened as part of their PHI).
  • For healthy volunteers, pregnancy will be excluded per verbal report.
  • Data will be collected regarding patient demographics including height and weight, abdominal circumference, blood pressure, comorbid medical conditions, triglycerides, HDL, fasting glucose and medication use (including prescription of antithrombotic agents, ACE inhibitors, angiotensin receptor blockers, beta blockers, calcium channel antagonists and HMG-CoA inhibitors).
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00855296

Contacts
Contact: Willie J Hudson, M.S. 615-322-5268 willie.j.hudson@vanderbilt.edu
Contact: Matthew Duvernay, Ph.D. 615-322-5268 matthew.t.duvernay@Vanderbilt.Edu

Locations
United States, Tennessee
Vanderbilt University Medical Center Recruiting
Nashville, Tennessee, United States, 37232
Contact: Willie J Hudson, M.S.     615-322-5268        
Sponsors and Collaborators
Vanderbilt University
Investigators
Principal Investigator: Heidi E. Hamm, Ph.D. Vanderbilt Universtiy Medical Center, Pharmacology
  More Information

No publications provided

Responsible Party: Vanderbilt University ( Heidi E. Hamm )
Study ID Numbers: 050182
Study First Received: March 2, 2009
Last Updated: March 31, 2009
ClinicalTrials.gov Identifier: NCT00855296     History of Changes
Health Authority: United States: Institutional Review Board

Study placed in the following topic categories:
Thrombin
Arterial Occlusive Diseases
Coronary Disease
Heart Diseases
Myocardial Ischemia
Acute Coronary Syndrome
Vascular Diseases
Arteriosclerosis
Ischemia
Coronary Artery Disease

Additional relevant MeSH terms:
Arterial Occlusive Diseases
Coronary Disease
Pathologic Processes
Disease
Heart Diseases
Myocardial Ischemia
Syndrome
Acute Coronary Syndrome
Vascular Diseases
Cardiovascular Diseases
Arteriosclerosis
Coronary Artery Disease

ClinicalTrials.gov processed this record on May 06, 2009